15:00 – 17:00: New horizons in the oncology treatment landscape
15:00 – 15:30 – Immune Checkpoint Inhibitors in Breast Cancer in 2021 – Prof. Dr. Christoph Zielinski
15:30 – 16:00 – CAR T cell Therapy for Blood Cancers – Adrian Bot MD. Ph.D.
16:00 – 16:30 – Novel strategies to prime and sustain the cancer – immunity cycle in immunologically cold tumors – Prof. Caius G. Radu
16:30 – 17:00 – Radiation therapy in oligometastatic diseases – Prof. Dr. Gabriel Kacso
17:00 – 17:20 – Satellite Symposium AstraZeneca – Imfinzi – The immunotherapy that changed the standard of care in Stage III Unresectable NSCLC – Prof. Dr. Rodica Anghel
17:20 – 17:40 – Satellite Symposium AstraZeneca – Tagrisso – standard of care for EGFR – mutated NSCLC patients – Prof. Dr. Tudor Ciuleanu
17:40 – 18:00 – Break
18:00 – 18:10 – Satellite Symposium Pfizer – Benefits of Lorviqua in NSCLC ALK+ patients – Dr. Mircea Dediu
18:10 – 18:30 – Satellite Symposium Bristol Myers Squibb – 5 years of experience with Opdivo 2L NSCLC – Sef Lucr. Dr Oana Trifănescu
18:30 – 20:30: Lung Cancer
18:30 – 19:00 – Picking up the most important advances in NSCLC in 2021 – Prof. Dr. Tudor Ciuleanu
19:00 – 19:30 – Debate Hyper progression
-
- Yes – Dr. Mircea Dediu
- No – Dr. Razvan Curcă
19:30 – 20:00 – Radiation therapy in the global NSCLC course of disease (curative stereotactic, adjuvant, non-resectable, oligometastatic) – Prof Dr. Rodica Anghel
20:00 – 20:30 – Tumor board – case presentations
15:00 – 17:00: Breast Cancer
15:00 – 15:30 – What makes TNBC a special entity – Prof. Dr. Rupert Bartsch
15:30 – 16:00 – The antibody-drug conjugates in the landscape of BC treatment – Conf. Dr. Alexandru Eniu
16:00 – 16:30 – Do all node-positive BC need a dose dense chemotherapy approach in an adjuvant setting? – Dr. Mircea Dediu
16:30 – 17:00 – Tumor board – case presentations
17:00 – 17:20 – Satellite Symposium AstraZeneca – Lynparza in Breast Cancer – Dare to redefine – Conf. Dr. Laurenția Galeș
17:20 – 17:40 – Satellite Symposium Pfizer – From Clinical Trials to Real World Practice: Charting a new standard in HR+/HER2- ABC – Dr. Raluca Mihăilă
17:50 – 18:10 – Break
18:10 – 18:30 – Sesiune educațională susținută cu sprijinul Novartis – Updates in HR+ HER2 – Advanced Breast Cancer – Dr. Dragoș Median
18:30 – 20:30: Colon cancer – Sesiune Educațională Susținută cu Sprijinul Servier Pharma
18:30 – 19:00 – Oxaliplatin in adjuvant setting: when and for how long? – Conf. Dr. Șerban Negru
19:00 – 19:30 – Pro and con Resectable liver metastases: Liver Metastasectomy upfront or after induction chemotherapy – Prof. Dr. Klaus Kaczirek
19:30 – 20:00 – When chemotherapy is no longer the first option in metastatic CRC – Prof. Dr. Gerald Prager
20:00 – 20:30 – Tumor board – case presentations
15:00 – 17:00: Melanoma
15:00 – 15:30 – Uncommon melanoma: uveal, mucosal, intestinal – Conf. Dr. Laurenția Galeș
15:30 – 16:00 – Preferred Adjuvant treatment for BRAF mutant melanoma – Prof. Dr. Dirk Schadendorf – Sesiune Educațională susținută cu sprijinul Novartis
16:00 – 16:30 – What to do when the standard immune and targeted therapies are exhausted? – Prof. Dr. Mario Mandala
16:30 – 17:00 – Tumor board – case presentations
17:00 – 17:30 – Satellite Symposium Janssen – Terapia hormonala inovatoare la pacientii cu mHSPC – Dr. Mircea Dediu
17:30 – 17:50 – Satellite Symposium Bristol Myers Squibb – Combined Imunotherapy with Opdivo and Yervoy, chances of long term survival for patients with metastatic melanoma and renal carcinoma – Dr. Raluca Mihăilă
17:50 – 18:10: Break
18:10 – 18:30 – Satellite Symposium Roche – Comprehensive Genomic Profiling in the evolving landscape of cancer – Dr. Dragoș Median
18:30 – 20:30: Ovarian cancer
18:30 – 19:00 – Picking up the most important advances in ovarian cancer in 2021 – Dr. Larisa Ciule
19:00 – 19:30 – First-line treatment in BRCA mutant ovarian cancer:
-
- PARP inhibitors preferred – Sef Lucrări Dr. Oana Trifănescu
- Bevacizumab preferred – Sef Lucrări Dr. Andreea Lăzescu
19:30 – 20:00 – The never-ending story of interval debulking surgery in ovarian cancer – Prof. Dr. Alexander Reinthaller
20:00 – 20:30 – Tumor board – case presentations
15:00 – 17:00: Head and neck
15:00 – 15:30 – What is new in radiation therapy techniques? – As. Univ. Dr. Toma Radu Valeriu
15:30 – 16:00 – Debate: Is induction chemotherapy a standard treatment in Head & neck tumors?
-
- Yes – Sef Lucrări Dr. Radu Mitrica
- No – As. Univ. Dr. Mihai Georgescu
16:00 – 16:30 – Benefits and detriments associated with the ICI administration:
-
-
- Benefits – As. Univ. Dr. Luiza Șerbănescu
- Detriments – As. Univ. Dr. Anca Zgură
-
16:30 – 17:00 – Tumor Board – case presentations
17:00 – 17:35 – Satellite Symposium MSD – Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma – Prof. Dr. Rodica Anghel
17:35 – 18:00: Break
18:00 – 18:20 – Satellite Symposium Astellas – Xtandi-WIN TIME – Conf. Dr. Laurentia Gales
18:30 – 20:30: Orphan tumors
18:30 – 19:00 – Sarcoma – Prof. Dr. Thomas Brodowicz
19:00 – 19:30 – Testicular cancer – Prof. Dr. Lucian Miron
19:30 – 20:00 – Neuroendocrine tumors – radionuclide therapy – Conf. Dr. Laura Rebegea
20:00 – 20:30 – Rare gynecological tumors – Dr. Claudia Ordeanu
Closing Remarks